CA2457056A1 - Compositions pharmaceutiques comprenant des conjugues de polysaccharides permettant l'inhibition des metastases ou la prevention de la recurrence des tumeurs malignes - Google Patents
Compositions pharmaceutiques comprenant des conjugues de polysaccharides permettant l'inhibition des metastases ou la prevention de la recurrence des tumeurs malignes Download PDFInfo
- Publication number
- CA2457056A1 CA2457056A1 CA002457056A CA2457056A CA2457056A1 CA 2457056 A1 CA2457056 A1 CA 2457056A1 CA 002457056 A CA002457056 A CA 002457056A CA 2457056 A CA2457056 A CA 2457056A CA 2457056 A1 CA2457056 A1 CA 2457056A1
- Authority
- CA
- Canada
- Prior art keywords
- metastasis
- recurrence
- inhibiting
- preventing
- malignant tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 title abstract 3
- 229920001282 polysaccharide Polymers 0.000 title abstract 3
- 239000005017 polysaccharide Substances 0.000 title abstract 3
- 206010027476 Metastases Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 230000009401 metastasis Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001-249717 | 2001-08-21 | ||
| JP2001249717 | 2001-08-21 | ||
| PCT/JP2002/008309 WO2003015826A1 (fr) | 2001-08-21 | 2002-08-16 | Compositions pharmaceutiques comprenant des conjugues de polysaccharides permettant l'inhibition des metastases ou la prevention de la recurrence des tumeurs malignes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2457056A1 true CA2457056A1 (fr) | 2003-02-27 |
| CA2457056C CA2457056C (fr) | 2008-07-22 |
Family
ID=19078678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002457056A Expired - Fee Related CA2457056C (fr) | 2001-08-21 | 2002-08-16 | Compositions pharmaceutiques comprenant des conjugues de polysaccharides permettant l'inhibition des metastases ou la prevention de la recurrence des tumeurs malignes |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1418947A1 (fr) |
| KR (1) | KR20040027972A (fr) |
| CN (1) | CN100372570C (fr) |
| AR (1) | AR035137A1 (fr) |
| AU (1) | AU2002328093B2 (fr) |
| BR (1) | BR0212036A (fr) |
| CA (1) | CA2457056C (fr) |
| HU (1) | HUP0401351A3 (fr) |
| IL (1) | IL160148A0 (fr) |
| MX (1) | MXPA04001599A (fr) |
| NO (1) | NO20041194L (fr) |
| NZ (1) | NZ530947A (fr) |
| PL (1) | PL368319A1 (fr) |
| RU (1) | RU2275913C2 (fr) |
| TW (1) | TWI313609B (fr) |
| UA (1) | UA75450C2 (fr) |
| WO (1) | WO2003015826A1 (fr) |
| ZA (1) | ZA200400917B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306314A (en) * | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
| FR2914305B1 (fr) | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | Dextran fonctionnalise par des amino-acides hydrophobes. |
| EP3693454A1 (fr) | 2008-07-16 | 2020-08-12 | Children's Medical Center Corporation | Dispositif simulateur d'organe comportant des microcanaux et ses procédés d'utilisation et de fabrication |
| AU2012262139B2 (en) * | 2011-06-02 | 2017-02-23 | Children's Medical Center Corporation | Methods and uses for ex vivo tissue culture systems |
| PL221351B1 (pl) | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Sposób otrzymywania nanocząstek polisacharydowych |
| KR102087017B1 (ko) | 2012-10-11 | 2020-03-10 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트 |
| EP2910573B1 (fr) * | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Conjugué anticorps-médicament produit par liaison par l'intermédiaire d'un lieur ayant une structure hydrophile |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| TWI718144B (zh) | 2015-05-04 | 2021-02-11 | 美商輝瑞股份有限公司 | Ｂ型鏈球菌多醣－蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途 |
| BR112017027690A2 (pt) | 2015-06-29 | 2018-10-09 | Daiichi Sankyo Co Ltd | método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco |
| EP3552626A4 (fr) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | Association d'un conjugué anticorps-médicament et d'un inhibiteur de point de contrôle immunitaire |
| JP6679762B2 (ja) | 2017-01-17 | 2020-04-15 | 第一三共株式会社 | 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート |
| TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
| CN117838880A (zh) | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
| EP3677589A4 (fr) | 2017-08-31 | 2021-04-21 | Daiichi Sankyo Company, Limited | Procédé amélioré de production d'un conjugué anticorps-médicament |
| CN117815404A (zh) | 2018-05-18 | 2024-04-05 | 第一三共株式会社 | 抗-muc1抗体-药物缀合物 |
| CN109481691A (zh) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | 吉西他滨-羧甲基多糖共轭物、制备方法及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0640622T3 (da) * | 1993-02-26 | 2000-10-23 | Drug Delivery System Inst Ltd | Polysaccharidderivat og lægemiddelbærer |
| SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| CA2192725C (fr) * | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Derives de la camptothecine |
| WO1997038727A1 (fr) * | 1996-04-15 | 1997-10-23 | Asahi Kasei Kogyo Kabushiki Kaisha | Composite medicamenteux |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| CN1058038C (zh) * | 1996-12-31 | 2000-11-01 | 中国科学院感光化学研究所 | 低收缩性光固化涂层材料及其制法和用途 |
| EA003398B1 (ru) * | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Лекарственный комплекс c полимерным носителем |
-
2002
- 2002-08-14 TW TW091118260A patent/TWI313609B/zh not_active IP Right Cessation
- 2002-08-15 AR ARP020103077A patent/AR035137A1/es unknown
- 2002-08-16 KR KR10-2004-7002566A patent/KR20040027972A/ko not_active Application Discontinuation
- 2002-08-16 HU HU0401351A patent/HUP0401351A3/hu unknown
- 2002-08-16 EP EP02762786A patent/EP1418947A1/fr not_active Withdrawn
- 2002-08-16 IL IL16014802A patent/IL160148A0/xx unknown
- 2002-08-16 NZ NZ530947A patent/NZ530947A/en not_active IP Right Cessation
- 2002-08-16 UA UA2004032071A patent/UA75450C2/uk unknown
- 2002-08-16 CA CA002457056A patent/CA2457056C/fr not_active Expired - Fee Related
- 2002-08-16 WO PCT/JP2002/008309 patent/WO2003015826A1/fr active IP Right Grant
- 2002-08-16 MX MXPA04001599A patent/MXPA04001599A/es unknown
- 2002-08-16 CN CNB028163176A patent/CN100372570C/zh not_active Expired - Fee Related
- 2002-08-16 AU AU2002328093A patent/AU2002328093B2/en not_active Ceased
- 2002-08-16 BR BR0212036-4A patent/BR0212036A/pt not_active IP Right Cessation
- 2002-08-16 PL PL02368319A patent/PL368319A1/xx not_active Application Discontinuation
- 2002-08-16 RU RU2004108141/15A patent/RU2275913C2/ru not_active IP Right Cessation
-
2004
- 2004-02-04 ZA ZA200400917A patent/ZA200400917B/en unknown
- 2004-03-19 NO NO20041194A patent/NO20041194L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200400917B (en) | 2004-08-25 |
| RU2004108141A (ru) | 2005-04-20 |
| AU2002328093B2 (en) | 2005-05-05 |
| IL160148A0 (en) | 2004-07-25 |
| CN1545423A (zh) | 2004-11-10 |
| PL368319A1 (en) | 2005-03-21 |
| KR20040027972A (ko) | 2004-04-01 |
| NO20041194L (no) | 2004-03-19 |
| CA2457056C (fr) | 2008-07-22 |
| TWI313609B (en) | 2009-08-21 |
| NZ530947A (en) | 2006-04-28 |
| BR0212036A (pt) | 2004-08-17 |
| CN100372570C (zh) | 2008-03-05 |
| MXPA04001599A (es) | 2004-07-08 |
| UA75450C2 (en) | 2006-04-17 |
| EP1418947A1 (fr) | 2004-05-19 |
| AR035137A1 (es) | 2004-04-14 |
| WO2003015826A1 (fr) | 2003-02-27 |
| RU2275913C2 (ru) | 2006-05-10 |
| HUP0401351A3 (en) | 2011-02-28 |
| HUP0401351A2 (hu) | 2004-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2457056A1 (fr) | Compositions pharmaceutiques comprenant des conjugues de polysaccharides permettant l'inhibition des metastases ou la prevention de la recurrence des tumeurs malignes | |
| EP1430061A4 (fr) | Compose d'inclusion contenant des derives de cucurbituril en tant que molecule receptrice et composition pharmaceutique les contenant | |
| AU5783300A (en) | Anilinoquinazolines as protein tyrosine kinase inhibitors | |
| DE69912952D1 (en) | Cyclosporine | |
| WO2003053368A3 (fr) | Derives de chalcone et leur utilisation dans le traitement de maladies | |
| CA2370245A1 (fr) | Composes de promedicaments anti-tumoraux actives par des enzymes | |
| PL337719A1 (en) | Pharmaceutic composition having enhanced anticarcinogenic activity and/or reduced side effects, containing an anticarcinogenic agwent and a derivative of hydroxamic acid | |
| TR200200717T2 (tr) | Terapötik kinazolin türevleri. | |
| CA2269923A1 (fr) | Compositions pharmaceutiques contenant une proteine du plasma | |
| EP2364730A3 (fr) | Préparations d'immunoglobuline disposant d'une stabilité améliorée | |
| WO2003079972A3 (fr) | Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs | |
| CA2163706A1 (fr) | Derives amino-acides de paclitaxel | |
| CA2303498A1 (fr) | Acides dioxocyclopentylhydroxamiques | |
| WO2001012233A3 (fr) | Formulation de peptide a liberation lente | |
| EP0394905A3 (fr) | Antagonistes d'acides aminés excitateurs | |
| GB0310919D0 (en) | Pharmaceutical compositions | |
| ATE249842T1 (de) | Zielgerichte arzneimittel abgabe für zulphonamide-derivate | |
| WO2000045800A3 (fr) | Effets immunosuppresseurs des derives de pteridine | |
| TR199900336T2 (xx) | EAA antagonistleri olarak tetrahidrokinolin t�revleri. | |
| WO2003086471A3 (fr) | Preparation liquide comprenant un derive de camptothecine et composition pharmaceutique pouvant etre preparee par lyophilisation de la preparation | |
| ATE317846T1 (de) | Phosphoramidat-prodrugs | |
| HK1055947A1 (en) | Novel branched substituted amino derivatives of 3-amino-1-phenyl-1H-Ä1,2,4Ütriazol, methods for producing them and pharmaceutical compositions containing them | |
| EP2239270A3 (fr) | Dérivés de peptides à faible poids moléculaire en tant qu'inhibiteurs de l'interaction laminine/nidogène | |
| TNSN00240A1 (en) | Heterocyclic derivatives | |
| AU5992500A (en) | Compound derived from an offset orf of the ice gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |